NCT07130617View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
EfficacySafetyMegestrol AcetateAdult Subject
Interventions
DRUG

Low dose of Megestrol Acetate Oral Suspension combined with standard therapy

A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.

DRUG

Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy

A single dose of 625 mg/day, administered once daily (QD) for 7 consecutive days.

DRUG

High dose of Megestrol Acetate Oral Suspension combined with standard therapy

A single dose of 937.5 mg/day, administered once daily (QD) for 7 consecutive days.

DRUG

Megestrol Acetate Oral Suspension Placebo combined with standard therapy

A single dose of 5 mL/day, administered once daily (QD) for 7 consecutive days.

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY